Amplia Therapeutics (ASX:ATX) said it opened two sites in the US, which will shortly start recruitment activities for its Amplicity trial, according to a Wednesday filing with the Australian bourse.

The trial will evaluate the company's lead drug, narmafotinib, in advanced pancreatic cancer patients, the filing said.

An additional three sites in the US will be initiated in the near future as recruitment continues, the filing added.

Shares of the company rose past 4% in recent Wednesday trade.